Literature DB >> 27439304

Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective.

Peter Yan1, Eng Kiat Kevin Tan2, Jason Chon Jun Choo3, Choon Fong Stanley Liew4, Titus Lau5, David D Waters6.   

Abstract

The link between cholesterol levels and atherosclerotic cardiovascular disease (ASCVD) is well-established. In Singapore, there is an increasing prevalence of risk factors for ASCVD. Like many Asian countries, Singapore's population is rapidly ageing and increasingly sedentary, which predisposes individuals to chronic health problems. Current international and local guidelines recommend statin therapy for the primary and secondary prevention of ASCVD. However, despite the effectiveness of statin therapy, some studies have highlighted that Asian patients with cardiovascular disease are not achieving target lipid goals. Furthermore, it is widely believed that the responses of Asians (both patients and physicians) to statin therapy are different from those of their Western counterparts. Experts convened in 2014 to determine the impact of current guidelines on clinical practice in Singapore. This review summarises the key findings and recommendations of these guidelines, and presents key principles to aid clinicians to manage the cardiovascular risk of their patients more effectively. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  Singapore; atherosclerosis; cardiovascular disease; lipids

Mesh:

Substances:

Year:  2016        PMID: 27439304      PMCID: PMC4958711          DOI: 10.11622/smedj.2016118

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  34 in total

Review 1.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Authors:  S Yusuf; S Reddy; S Ounpuu; S Anand
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

2.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies.

Authors:  S Yusuf; S Reddy; S Ounpuu; S Anand
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

3.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Authors:  Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

4.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.

Authors:  Edmund Lee; Stephen Ryan; Bruce Birmingham; Julie Zalikowski; Ruth March; Helen Ambrose; Rachael Moore; Caroline Lee; Yusong Chen; Dennis Schneck
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

5.  A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.

Authors:  K Y Wang; C T Ting
Journal:  Jpn Heart J       Date:  2001-11

6.  Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.

Authors:  Akira Yamamoto; Kikuo Arakawa; Jun Sasaki; Yuji Matsuzawa; Kaoru Takemura; Motoo Tsushima; Takao Fujinami; Hiroshi Mabuchi; Hiroshige Itakura; Nobuhiro Yamada; Takayoshi Toyota; Shinichi Oikawa
Journal:  J Atheroscler Thromb       Date:  2002       Impact factor: 4.928

Review 7.  Update in renal transplantation.

Authors:  Colm C Magee; Manuel Pascual
Journal:  Arch Intern Med       Date:  2004-07-12

8.  Cholesterol, coronary heart disease, and stroke in the Asia Pacific region.

Authors:  X Zhang; A Patel; H Horibe; Z Wu; F Barzi; A Rodgers; S MacMahon; M Woodward
Journal:  Int J Epidemiol       Date:  2003-08       Impact factor: 7.196

9.  Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.

Authors:  Chau-Chung Wu; Rody Sy; Vichai Tanphaichitr; Arthur Tan Teow Hin; Slamet Suyono; Yuan-Teh Lee
Journal:  J Formos Med Assoc       Date:  2002-07       Impact factor: 3.282

10.  Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.

Authors:  Yasushi Saito; Yuichiro Goto; Aaron Dane; Kristina Strutt; Ali Raza
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

View more
  3 in total

1.  Changes in the practice of cardiology: therapies at the forefront of science.

Authors:  Joshua Ping-Yun Loh; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

2.  Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II.

Authors:  Kian-Keong Poh; Chee Tang Chin; Khim Leng Tong; Julian Ko Beng Tan; Jee Seong Lim; Weixuan Yu; Martin Horack; Ami Vyas; Dominik Lautsch; Baishali Ambegaonkar; Philippe Brudi; Anselm K Gitt
Journal:  Singapore Med J       Date:  2019-02-18       Impact factor: 1.858

Review 3.  Nonadherence to statins: individualized intervention strategies outside the pill box.

Authors:  Peter Lansberg; Andre Lee; Zhen-Vin Lee; Kannan Subramaniam; Sajita Setia
Journal:  Vasc Health Risk Manag       Date:  2018-05-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.